You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 9, September 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Randomized Controlled Trial
 •Prognosis/ Outcomes
 •Neoplasms
 •Dermatologic Surgery
 •Alert me on articles by topic

Five-Year Follow-up of a Randomized, Prospective Trial of Topical Methyl Aminolevulinate Photodynamic Therapy vs Surgery for Nodular Basal Cell Carcinoma

Lesley E. Rhodes, MD, FRCP; Menno A. de Rie, MD; Ragna Leifsdottir, MD; Raymond C. Yu, MD, FRCP; Ingeborg Bachmann, MD; Victoria Goulden, MD, FRCP; Gavin A. E. Wong, MRCP; Marie-Aleth Richard, MD; Alex Anstey, MD, FRCP; Peter Wolf, MD

Arch Dermatol. 2007;143(9):1131-1136.

Objective  To compare 5-year lesion recurrence rates in primary nodular basal cell carcinoma treated with topical methyl aminolevulinate photodynamic therapy (PDT) or simple excision surgery.

Design  Prospective, randomized, multicenter study.

Setting  University hospital dermatology departments.

Patients  A total of 97 patients, 50 with 53 lesions treated with methyl aminolevulinate PDT and 47 with 52 lesions treated by excision surgery, were included in the per protocol analysis. Of the lesions treated with methyl aminolevulinate PDT and surgery, 49 and 52, respectively, showed complete clinical response at 3 months after treatment and were observed for long-term outcome evaluation.

Interventions  Topical methyl aminolevulinate cream, 160 mg/g, applied for 3 hours before illumination (75 J/cm2 of red light at 570 to 670 nm) on 2 or 4 occasions (12 [23%] of 53 lesions); or excision surgery.

Main Outcome Measures  Histologically confirmed lesion recurrence, sustained lesion complete response rate (time-to-event analysis), and investigator assessment of cosmetic outcome, 5 years after the last treatment.

Results  At 5 years, recurrence was documented in 7 (14%) of 49 lesions (95% confidence interval [CI], 6%-27%) treated with methyl aminolevulinate PDT vs 2 (4%) of 52 lesions (95% CI, 1%-13%) treated with excision surgery (P = .09). Estimated sustained lesion complete response rates were 76% (95% CI, 59%-87%) and 96% (95% CI, 84%-99%), respectively (P = .01). More patients treated with methyl aminolevulinate PDT than surgery had an excellent or good cosmetic outcome: 27 (87%) of 31 patients (95% CI, 70%-96%) vs 19 (54%) of 35 patients (95% CI, 37%-71%) (P = .007).

Conclusions  Long-term follow-up indicates superior efficacy of surgery to methyl aminolevulinate PDT in nodular basal cell carcinoma. However, methyl aminolevulinate PDT is also an effective treatment for this indication and exhibits a more favorable cosmetic outcome.


Author Affiliations: Photobiology Unit, Departments of Dermatology, University of Manchester and Salford Royal Foundation Hospital, Manchester (Dr Rhodes), University College Hospital, London (Dr Yu), Leeds General Infirmary, Leeds (Dr Goulden), and Royal Liverpool University Hospital, Liverpool (Dr Wong), England; Academic Medical Centre, Amsterdam, the Netherlands (Dr de Rie); Norra Älvsborgs Länssjukhus, Trollhättan, Sweden (Dr Leifsdottir); Haukeland Hospital, Bergen, Norway (Dr Bachmann); Hôpital Sainte-Marguerite, Marseille, France (Dr Richard); University Hospital of Wales, Cardiff (Dr Anstey); and Medical University Graz, Graz, Austria (Dr Wolf).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Photodynamic Therapy vs. Excision for BCC
Journal Watch Dermatology 2007;2007:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.